Krainer Adrian R.

Director Krainer sells 33,243 STOK shares at $39.74; stock now $36.48. Frequent seller pattern continues.

Director Adrian R. Krainer sold 33,243 shares at $39.74 on 2026-03-10, reducing holdings by 10.5% to 283,302 shares and generating $1,320,963.79. This is the fourth open-market sale by Krainer in recent months—he also sold at STOK on 2025-11-24, 2025-11-14 (twice)—indicating a sustained, recurring pattern of share liquidation rather than isolated timing-driven activity. Stoke Therapeutics remains unprofitable with net income of $-38,347,000.00 in its most recent full fiscal year, though revenue grew 316.3% year-over-year and the company carries a $2.1B market cap. The current price of $36.48 sits 4.9% below the 52-week high and has risen 12.6% over 90 days; across Krainer's prior three sales at this ticker, the 90-day returns averaged +15.4%, +19.8%, and +16.7%—all positive, indicating his prior sales were not well-timed from a directional standpoint (stock subsequently rose after each sale). The recurring, high-frequency selling pattern warrants investor attention to whether it reflects scheduled portfolio management or is responsive to company-specific developments.

Director Krainer Adrian R. sold 40,472 shares of STOK at $29.72 on 2025-11-14; holds 323,774 shares post-sale.

Krainer, a director, sold 40,472 shares (40.5K shares) for $1,202,718.57 ($1.2M), reducing his holdings by 11.1%. The sale occurred at $29.72, which was 5.0% below the current price of $31.21 and 12.3% below the 52-week high of $35.60. Stoke Therapeutics is unprofitable with net income of $-38,347,000.00 ($-38.3M) over its most recent full fiscal year, though it posted strong annual revenue growth of +316.3%. The timing of this sale follows two prior sales by the same insider at this ticker on 2025-11-14, with a third sale also on 2025-11-24, forming a pattern of consecutive dispositions. His cross-ticker track record includes only 2 prior sells with no well-timed outcomes measurable yet at this ticker.

Director Krainer sells 40,472 shares at $26.98 avg for $1.1M; retains 364.2K shares at unprofitable biotech

Adrian R. Krainer executed 2 separate sales totaling 40,472 shares for $1,092,058.26 on 2025-11-14, reducing his holdings by 10.0% from 404,718 to 364,246 shares. The stock has declined 18.8% from its 52-week high of $35.60 and fallen 13.8% over the past 30 days, despite a 49.7% surge over 90 days. Stoke remains deeply unprofitable with annual net income of $-38,347,000.00 against quarterly revenue of $10,632,000.00, though full-year revenue growth of 316.3% reflects substantial top-line expansion. The sale occurs at a blended price of $26.98, below the current market price of $28.92, and Krainer retains substantial ongoing exposure at 364,246 shares post-transaction, indicating continued material ownership despite the liquidation.